OpenAI Acquires Orchestra Bio to Integrate AI Agents into Drug Development Workflows
OpenAI has acquired Orchestra Bio, a startup building AI agents for pharmaceutical program management, integrating its technology into the Rosalind life sciences unit to automate clinical trial monitoring and coordination.
ImportanceMaterialEvidenceE3 inspectableWrite-upQuick
OpenAI Group PBC announced on October 20, 2026, that it has acquired Orchestra Bio Inc., a drug development software startup. Orchestra Bio builds artificial intelligence agents designed to help pharmaceutical teams keep development programs on track. Its staff and technology will now sit inside OpenAI’s Rosalind life sciences unit.
OpenAI states that getting a new medicine through U.S. regulatory approval takes 10 to 15 years on average, often hindered by disconnected systems between departments and external partners. Orchestra’s agents take over the monitoring of studies, tracking finances, and resolving clinical trial scheduling problems. For instance, if a failed manufacturing batch threatens to push back a trial, the software works out which activities and timelines are hit and weighs ways to respond, though people still make the final call.
Terms of the deal were not disclosed. This marks OpenAI’s second healthcare-related acquisition this year, following the January purchase of medical records company Torch Health. Rival Anthropic also entered the space in April by acquiring AI biotech startup Coefficient Bio for approximately $400 million. Drugmakers such as Novo Nordisk A/S and Moderna Inc. are already utilizing OpenAI’s Rosalind tools for research execution and experimental planning.